Skip to main content
. 2014 May 13;5(11):3607–3610. doi: 10.18632/oncotarget.1964

Table 1. Urine and plasma cell-free DNA BRAF VGOOE mutations.

Patient# Age at diagnosis Gender Involvement Urine BRAF VGOOE/WT Plasma BRAF VGOOE/WT Patient Tissue BRAFstatus
1 59 Male CNS, cardiac, bones, renal V600E (22.590%) V600E (8.598%) V600E
2* 43 Male CNS, bones, renal V600E (0.311%) V600E (1.522%) V600E
3 26 Male Skin Wild-type (0.010%) Wild-type (0.063%) Wild-type
4 71 Female Bones, lymph nodes V600E (0.159%) Wild-type (0.047%) Unknown**
5 43 Female CNS, bones V600E (4.940%) V600E (0.261%) Unknown**
6 49 Male CNS, cardiac, omentum, retroperitoneum Wild-type indeterminate (0.079%) Wild-type (0.048%) Unknown**

CNS; central nervous system

*

Urine and plasma collected on different dates

**

lnsuficient tissue for molecular analysis

HHS Vulnerability Disclosure